New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2012
05:13 EDTDECK, ZNGA, AMRC, ZIP, BAC, HD, DNDN, GLD, WFMI, LOW, EXC, SBUX, CL, SIRI, PM, NLY, AGNC, CMI, PCAR, REGN, PFE, KO, MSFT, YHOO, AAPL, IBM, PCYC, JPM, MNST, HSTM, CONN, SXCI, QCOR, IDIX, VVUS, MDVN, PCLN, GS, ACATJim Cramer's "Mad Money"
Wednesday was Jim Cramer's anniversary of his "Mad Money" TV show. He said it's time to come off the sidelines, sell those bank CDs earning 0.4% interest and invest in great American companies. Cramer said today's markets are being driven by pure growth, U.S. growth. He said everything from health care to retail to technology, even the homebuilders, are just beginning to show sustainable recoveries. Stocks like JPMorgan Chase (JPM) and IBM (IBM), are both leading the charge. Then there's Apple (AAPL) Cramer said while some investors can't fathom Apple's historic rise, he remembers a time when Coca-Cola (KO) and Pfizer (PFE) were the most valued companies on Wall Street. Apple is so much more than just a technology company, he said, adding it's a communications, education and entertainment company as well, all of which makes it worth its valuation. Cramers said the markets can most certainly take out its recent highs and march into bull-market mode, with a pickup in commercial construction and improved job growth looming just around the corner. Cramer recapped his "Magnificent Seven" speculative stocks to show viewers just how lucrative this under-rated method of investing can be. He said that every investor should have one spot in their portfolio dedicated to a speculative stock that adds excitement to their holdings. Cramer's magnificent seven stocks included Pharmacyclics (PCYC), a stock up 393% over the past 12 months, Medivation (MDVN), a biotech up 320%, Idenix Pharmaceuticals (IDIX), up 277%, and Vivus (VVUS), up 224%. Rounding out the seven were Arctic Cat (ACAT), which has risen 204% in 12 months, Conn's (CONN), up 211% and HealthStream (HSTM), which is up 192%. Next, Cramer also highlighted the seven best stocks that he's recommended since "Mad Money" first aired back in 2005, a list that exemplifies what "staying in the game" is all about. His top seven recommendations included Monster Beverage (MNST), which has risen 1,600% over the past seven years, the biotech company Regeneron (REGN), up 1,700% over seven years and Medivation (MDVN), the only company to make both of Cramer's lists, up 1,800%. The list also included Green Mountain Coffee Roasters (GMCR), a stock that despite huge losses recently, is still up 2,700% over seven years, SXC Health Solutions (SXCI) up 2800%, travel site Priceline.com (PCLN), up 2,850% and finally, Questcor Pharmceuticals (QCOR), which has rallied an astounding 7,066% over seven years. Cramer said when companies are riding long-term trends, their successes can turn into huge gains for shareholders. Next, Cramer responded to a New York Times op-ed piece chastising Goldman Sachs (GS), saying that the company often put its own interests ahead of those of its clients. Cramer said he didn't see any of this type of behavior when he worked for Goldman years ago. He said while he's sure that many of Goldman's employees are still committed to doing right by clients, perhaps this article can serve as a wake-up call for the firm to do even better for its clients, even if that means being less profitable in the short term. MAD TWEETS: Cramer said that Microsoft (MSFT) was a good stock, Yahoo (YHOO) was a bad one and Sirius XM Radio (SIRI) was a speculative one. Deckers Outdoor (DECK), said the warm winter hit this cold-weather shoemaker hard. Cramer was bullish on Starbucks (SBUX). Restructuring is working at Lowes (LOW) but he still prefers Home Depot (HD), and with gold stocks still suffering, he still likes the SPDR Gold Shares (GLD). Finally when asked about ZipCar (ZIP), Cramer said if investors want to invest in a recent IPO, he'd go with mobile game maker Zynga (ZNGA). LIGHTNING ROUND: (Bullish) ECL;PM; PCAR; CMI; AGNC; NLY; AMRC; EXC; WFMI. (Bearish) DNDN; BAC. Reference Link
News For DECK;SIRI;NLY;AGNC;YHOO;MSFT;CMI;GS;PCLN;PCAR;QCOR;SXCI;PM;REGN;MNST;CL;HSTM;CONN;ZNGA;ACAT;IDIX;ZIP;VVUS;MDVN;BAC;HD;JPM;PCYC;DNDN;PFE;KO;GLD;WFMI;AAPL;IBM;LOW;EXC;SBUX;AMRC From The Last 14 Days
Check below for free stories on DECK;SIRI;NLY;AGNC;YHOO;MSFT;CMI;GS;PCLN;PCAR;QCOR;SXCI;PM;REGN;MNST;CL;HSTM;CONN;ZNGA;ACAT;IDIX;ZIP;VVUS;MDVN;BAC;HD;JPM;PCYC;DNDN;PFE;KO;GLD;WFMI;AAPL;IBM;LOW;EXC;SBUX;AMRC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | all recent news | >>
August 8, 2014
08:42 EDTMSFTMicrosoft has made strong progress in cloud, says Pacific Crest
Subscribe for More Information
08:32 EDTMSFTVMware, others could benefit from increased cloud adoption, says Pacific Crest
Subscribe for More Information
08:27 EDTMDVNMedivation price target raised to $105 from $100 at Brean Capital
Brean Capital raised its price target on Medivation to $105 from $100 following its Q2 report, citing raised guidance for Xtandi sales, royalties, and milestone payments and the potential for Xtandi to receive FDA approval in September to be used in the pre-chemo setting. Brean keeps it Buy rating on the stock.
08:21 EDTMNSTOptions expected to be active
Subscribe for More Information
08:17 EDTPCYCPharmacyclics announces Jesse McGreivy to step down from Chief Medical Officer
Subscribe for More Information
08:14 EDTMNSTMonster Beverage results show potential of foreign markets, says BMO Capital
Subscribe for More Information
07:45 EDTQCORMallinckrodt price target lowered to $77 from $90 at Leerink
Leerink lowered its price target for Mallinckrodt (MNK) shares to $77 citing a heightened risk profile from the Questcor (QCOR) acquisition and significant earnings concentration in Acthar. The firm says it remains on the sidelines with a Market Perform rating on Mallinckrodt.
07:44 EDTQCORMallinckrodt remains favorite specialty pharmaceutical name, says UBS
UBS said Mallinckrodt (MNK) remains its favorite specialty pharmaceutical name following the company's update on its merger with Questcor (QCOR). The firm sees estimates increasing following the close of the transaction, the divestiture of the Medical Imaging division, and the reinvestment in higher margin assets. UBS has a Buy rating with a $94 price target on Mallinckrodt.
07:40 EDTMNSTMonster Beverage upgraded to Neutral from Underperform at Longbow
Subscribe for More Information
07:33 EDTMDVNMedivation price target raised to $90 from $85 at UBS
Subscribe for More Information
07:31 EDTAAPLChina refutes report of Apple product procurement ban, Re/code reports
Subscribe for More Information
07:23 EDTGS, JPMLevin probe of Goldman, JPMorgan commodity trading nears end, Reuters says
Senator Carl Levin's investigators have met with representatives from Goldman Sachs (GS) and JPMorgan (JPM) in recent weeks as his office wraps up its probe of the bank's commodity trading businesses, which could potentially reveal abuses in energy and metals markets, according to Reuters, citing sources familiar with the matter. Executives from the banks may appear at a hearing as early as September, the report added. Reference Link
07:18 EDTGS, JPM, BACRegulators direct banks to steer mortgage aid to hard-hit areas, FT says
Subscribe for More Information
06:44 EDTIBMNew IBM chip identifies patterns, NY Times says
IBM has developed a new type of computer chip that tries to imitate the pattern identifying powers of human brains, according to The New York Times. The chip could eventually perform calculations that today's supercomputers are not capable of, the newspaper added. Reference Link
06:39 EDTPFEPfizer faces torrent of Lipitor suits, Reuters says
Subscribe for More Information
06:30 EDTJPMCitigroup, Accenture employ tech workers in Argentina, Bloomberg says
Subscribe for More Information
06:11 EDTSBUXOSI withdraws products made in Shanghai in response to food scandal
After dealing with a food scandal, OSI China, parent company of Shanghai Husi Food, announced the withdrawal of products produced in Shanghai. The company said, "Husi is the subject of company and government investigations and it is proceeding smoothly. While there have been no reported illnesses linked to any Shanghai Husi products, recovering this production is an important step in facilitating the investigations and rebuilding the respect and trust of our customers, the government and the people of China. With assistances and guidance provided by Shanghai FDA, we have started the recovery process of products in question in a comprehensive and orderly." Worldwide brands such Yum! Brands (YUM) McDonald's (MCD) and Starbucks (SBUX) were affected by the scandal in China. Reference Link
06:01 EDTYHOOYahoo to strengthen email encryption for users, Mashable reports
Subscribe for More Information
05:54 EDTGLDSPDR Gold Trust overall implied volatility at 14; 26-week average is 15
Subscribe for More Information
05:45 EDTZNGAZynga price target lowered to $3 from $4.50 at Piper Jaffray
Piper Jaffray lowered its price target for Zynga shares to $3 after delayed game launches drove the company's Q2 miss and reduced outlook. Piper says it is taking a "wait and see approach" on Zynga's entrance into two new game genres with the NFL and Tiger Woods. It keeps a Neutral rating on the stock.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use